Clinical trials: Alzheimers Disease, open to volunteers
Cognitive Dysfunction
Flutemetamol F 18 Injection Formulation Comparison
VIZAMYL (flutemetamol F 18 injection) is a drug used during Positron Emission Tomography (PET) brain scans. It helps doctors detect the presence of amyloid protein, which is associated with Alzheimer's disease and other…
- Trial name
- NCT07873463
- Testing
- GE-287, Vizamyl
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- GE Healthcare
Alzheimer Disease
German Registry of Alzheimer's Disease Treated With Transcranial Pulse Stimulation
This study will primarily investigate the safety and secondarily the effect and applicability of Transcranial Pulse Wave Stimulation (TPS) for the treatment of Alzheimer's disease in the context of a PMCF study (Post-Market…
- Trial name
- GE-R-A-TPS (NCT06313944)
- Testing
- Registry
- Where
- 6 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Alzheimer's Disease
Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study
The purpose of this study is to see if a special light treatment, called photobiomodulation, can help people with memory problems such as Mild Cognitive Impairment or Mild Dementia due to Alzheimer's disease.
- Trial name
- NCT07224607
- Testing
- Photobiomodulation
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Cedars-Sinai Medical Center
Alzheimer Disease, Mild Cognitive Impairment (MCI)
Biomarker-based Trial of NPC-1 for Alzheimer's Pathology
This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
- Trial name
- NPC1-AD (NCT07236190)
- Testing
- natural product combination-1 (NPC1)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Alzheimer s Disease, Dementia
CommunityRx-Dementia + Peer Navigation (CRxDpeer)
The CRxDpeer intervention, delivered by a trained peer navigator, in practice called a "peer mentor", includes three evidence-based components: (a) focused education about common social (e.g., food and housing insecurity) and…
- Conditions
- Alzheimer s Disease, Dementia, Caregiver, Loneliness
- Trial name
- CRxDpeer (NCT07346183)
- Testing
- CommunityRx-Dpeer
- Where
- United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Down Syndrome-Associated Alzheimer's Disease (DS-AD)
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
The purpose of the study is to evaluate the effect of mivelsiran in adult participants with early-stage DS-AD and to characterize the safety, tolerability, and pharmacodynamics (PD) of mivelsiran.
- Trial name
- NCT07636811
- Testing
- Mivelsiran
- Where
- 10 sites in United States, Spain
- Volunteers
- 58 people
- Sponsor
- Alnylam Pharmaceuticals
Alzheimer's Disease
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild…
- Trial name
- PrevenTRON (NCT07717411)
- Testing
- Trontinemab
- Where
- 34 sites in United States, Argentina and 5 more
- Volunteers
- 1,600 people
- Sponsor
- Hoffmann-La Roche
Alzheimers Disease
A Post Authorization Registry Study of Participants Treated With LEQEMBI
To describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities-edema (ARIA-E), ARIA microhemorrhage and hemosiderin deposit (ARIA-H), and intracerebral hemorrhage greater than 1 cm…
- Trial name
- NCT07762092
- Testing
- No Intervention
- Where
- 17 sites in Canada
- Volunteers
- 400 people
- Sponsor
- Eisai Limited
Dementia, Alzheimer's Disease and Related Dementias
HomeCare Medication Management for People With Dementia
This study will evaluate whether the HomeCare medication management system can improve medication adherence and related outcomes for adults age 65 and older living with dementia, Alzheimer's disease, or related dementias.
- Trial name
- NCT07872072
- Testing
- HomeCare
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- HiDO Technologies
Grief
A Grief Support App for Adults Experiencing Bereavement
Losing a loved one is a difficult experience. Some people may require psychological support, but even for those who do not, grief can often feel overwhelming.
- Trial name
- NCT07862244
- Testing
- Self-guided grief app (Daybreak), Waiting list
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- Medical Research Council Cognition and Brain Sciences Unit
Alzheimer's Disease, Blood Brain Barrier
Pilot Clinical Trial to Assess the Safety of NMS-01 in Patients With Mild to Moderate Alzheimer's Disease
A single-center, single-arm, prospective, open-label, pilot clinical trial to evaluate the safety and efficacy of the Focused ultrasound stimulator system (NMS-01) for transient Blood-Brain Barrier (BBB) opening in patients with…
- Trial name
- NMSBBBOYUSH01 (NCT07869238)
- Testing
- NMS-01
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Neumous Inc.
Alzheimer's Disease
An Observational Study of LEQEMBI in Routine Clinical Practice in Taiwan
The primary purpose of this study is to describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities (ARIA)-oedema/effusion (ARIA-E), ARIA-microhemorrhage and haemosiderin deposit…
- Trial name
- NCT07869264
- Testing
- No Intervention
- Where
- 12 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- Eisai Taiwan Inc.
Neurodegenerative Diseases, Dementia
Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis
This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network.
- Trial name
- NAVAIDD (NCT06339190)
- Testing
- Venepuncture
- Where
- 2 sites in Australia
- Volunteers
- 1,000 people
- Sponsor
- Monash University
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Trial name
- MINDSET 2 (NCT06976203)
- Testing
- KarXT, KarX-EC
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 586 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer's Disease
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
- Trial name
- NCT07011745
- Testing
- Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule
- Where
- 143 sites in United States, Argentina and 12 more
- Volunteers
- 426 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer's Disease
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
The purpose of this study is to: Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after…
- Trial name
- NCT07214727
- Testing
- ALN-5288
- Where
- 13 sites in Canada, Netherlands and 2 more
- Volunteers
- 50 people
- Sponsor
- Alnylam Pharmaceuticals
Alzheimers Disease Related Dementias
Evaluating the Effectiveness of the Health App Recommendation Tool
This study aims to assess the effectiveness of the Health App Recommendation Tool (HART), an evidence-based tool that evaluates app features and matches them to the needs, abilities, and preferences of individuals with…
- Trial name
- HART (NCT07216716)
- Testing
- Health App Recommendation Tool (HART)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Cognitive Dysfunction, Lewy Body Disease
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily…
- Conditions
- Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
- Trial name
- NCT07589595
- Testing
- Donanemab
- Where
- 72 sites in United States, Japan and 2 more
- Volunteers
- 350 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Amyloid
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
The purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and if they remove clumps of protein…
- Conditions
- Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers
- Trial name
- NCT07787169
- Testing
- LY4405094, Florbetapir F18, Florbetaben F 18
- Where
- 18 sites in United States, China and 1 more
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease (AD), Early Alzheimer's Disease
The Effect of Urolithin A (Mitopure®) on Alzheimer's Disease
The overall aim of MITO-AD is to evaluate if the nutritional supplement urolithin A is associated with favourable changes in Alzheimer's disease-related biomarkers, cognitive measures, and safety/tolerability outcomes in…
- Conditions
- Alzheimer's Disease (AD), Early Alzheimer's Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
- Trial name
- Mito-AD (NCT07842146)
- Testing
- Urolithin A
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- University Hospital, Akershus